1. Innovations to Improve the Primary and Secondary Care Collaboration in the Management of Diabetic Related Kidney Disease Julie Lewis DSN. Renal and Diabetes Centre Glan Clwyd Hospital Denbighshire North Wales.

2. AIMS Review incidence / prevalence of Diabetes and Diabetic Nephropathy Share experience in the development of our Diabetic Nephropathy Service to date

5. DIABETIC NEPHROPATHY Gradually progressive condition associated with increased risk of cardiovascular disease, significantly impacting mortality if left to progress without detection or treatment. Incidence: Increasing. Prevalence : 10 – 40% Leading cause of ESRD. Diabetic nephropathy is now the single most common cause of CKD in the US and Europe.

6. What is Diabetic Renal Disease? Dipstick – ve: Microalbuminuria 1) Albumin - >20mg/l 2) Albumin Excretion Rate (AER) : 20- 200µg/min 3) Albumin Creatinine Ratio(ACR) - >2.4 Males >3.5 mg/mmol cr Females Dipstick –ve: renal impairment without proteinuria : MacIsaac RJ et al Nonalbuminuria Renal Insufficiency in Type 2 Diabetes Diabetes Care 27:195-200 Dipstick +ve: Macroalbuminuria(+/- Renal Impairment) AER >200µg/min or ACR >30 or 24 urinary protein >0.3g/day ( diabetic nephropathy)

7. Innovation 1. 2001 - 2002 6 Primary Care doctors (GPs) + Practice Nurses and Receptionists Renal/Diabetes Research Nurse Specialist Nephrologists Diabetologists Radiologist Chemical Pathologist Audit Administrator

8. Objectives Primary Care audit to establish no.T2DM screening for microalbuminuria Prevalence of MA in T2DM in our region Establish the best testing method (accuracy and compliance) Establish whether effective screening and management for MA in T2DM can happen in Primary Care

9. Main Findings Patients were not being screened for MA Using AER had low patient compliance (30%) What was our prevalence of MA? – 22% Lab acquired equipment for ACR(patient compliance improved to 83%) Produced local screening and treatment guidelines for diabetic renal disease

10. Screening for Diabetic Renal Disease Early Morning Urine for Albumin / Creatinine Ratio ACR (mg/mmol cr) < 2.5 Men < 3.5 Women > 2.5 Men > 3.5 Women Repeat ACR Annually Repeat ACR within 1 Month REPEAT ACR < 2.5 Men <3.5 Women >2.5 Men >3.5 Women < 2.5 Men < 3.5 Women > 2.5 Men > 3.5 Women Start: 1ACEi or A11RA 2Aspirin Ace-I: Angiotensin Converting Enzyme Inhibitor A11RA:Angiotensin 2 Receptor Antagonist

11. Treatment Guidelines for Diabetic Renal Disease The following ACE inhibitors (ACEi) and Angiotensin II Receptor Antagonist (AII RA) are licensed for treatment of diabetic renal disease – accepted by D&T and LHB vTitrate start dose at 2 weekly intervals, to target dose. Check BP at each dose increment and reduce dose if symptomatic hypotension develops.Repeat ACR or 24hr urinary protein every 3-6 monthly. vCheck U&Es before, 1 week after initiating and after dose increase of ACEi or AIIRA. STOP ACEi or AIIRA if serum creatinine rises c GFR drops >20% above baseline or if hyperkalaemia (potassium >6.0mml/l) develops. vAim for the following targets and advise patient to stop smoking: rBP < 130 / 70 rHbA1C < 7.0 rCholesterol < 5.0mmol/l vRefer to diabetic nephropathy clinic if a) creatinine >150µmol/l or rises >20% above baseline b) micro or macroalbuminuria continues to rise, despite target doses of ACEi or AIIRA c) nephrotic syndrome develops. Arrange renal ultrasound scan. vDo not use ACEi or AIIRA in pregnancy or patients planning pregnancy, bilateral renovascular disease, aortic stenosis.

12. Impact Results of this study with screening and treatment guidelines communicated to all GP’s and P/N’s No. of screening tests for Microalbuminuria using the ACR increased

13. Innovation 2 Satellite clinics for T2DM patients identified with microalbuminuria Opportunity to develop skills and knowledge in Primary care Reinforced screening and treatment guidelines for diabetic kidney disease

14. SATELLITE CLINIC INTERVENTIONS N=62 88% Needed life-modifying advice 59% Medication changes made 30% Had renal impairment and transferred to Hospital clinic: US Kidneys - all patients Renal MRA - 9 patients (no RAS) Renal Biopsy - 4 patients

15. Findings Simple innovative measures improved the primary secondary care interface and enhanced the screening and management of diabetic renal disease and its associated risk factors in our region Specialist support to implement these measures requires continuity to be fully effective, but has the potential to enable the majority of people with Diabetic Renal Disease to be effectively managed with evidence based guidelines in primary care.

16. Impact Raised awareness Improved communication Coinciding with GMS contract Increase ACR screening further

17. MA Testing – on the Increase!

18. Impact Clear referral guidelines congested Secondary care diabetic nephropathy clinic Unacceptable waiting list for this high risk group

19. Innovation 3 Increased referrals to secondary care. Review current service. Essential to re-structure service provision for diabetic nephropathy.

20. Clinic Pathway Referral Primary Care Secondary care diabetes clinic Specialist Physician - New patient assessment Investigation Diagnosis Treatment Plan Nurse-led ReviewPhysician review Low Clearance Clinic Supported discharge To P.C Continued secondary care review

21. Developing a Nurse-led Diabetic Nephropathy Review Service Professional development Education – skills and knowledge –Competence –Patient protection Treatment plan – Evidence based Optimise Modifiable Risks – reduce progression of Diabetic Nephropathy Structured patient education – strategies for self-management

22. Nurse-led Review Implement action plan Inclusive – sharing knowledge Follow up visits to evaluate effectiveness of clinical interventions Pre testing Inclusive – discussing results and treatment plan – increasing understanding Telephone clinics – glycaemic control Continuity – supporting compliance and optimising control Promote partnership approach to behaviour / lifestyle changes Realistic goal setting Motivation Responsibility

23. Effective strategies for Self- Management Realistic Collaborative Patient centred Identify barriers for self-management Knowledge Helplessness / frustration Grieving for loss of health – denial / indifference Continued Support / encouragement

24. Nurse-led Review - Collaboration Promote knowledge and understanding Offer advice Coaching and encouragement Empowerment – informed decision making Weigh up options Make choices

25. Nurse led Clinic - Benefits Cost effective Increased diabetic nephropathy review slots by 250 per year No DNA’s Audit of clinical effectiveness and patient satisfaction - Summer 2006 Encourage Practice Nurses to attend clinic

26. Nurse-led Clinic Limitations One session per week – clinic One session per month – telephone clinic Collaboration between Primary and Secondary care hindered by poor IT provision Numbers still increasing - ? Group education

27. Link with Policy Diabetes NSF / Renal NSF / NICE / Chronic Disease Management strategies –Early detection –Delay progression –Structured education / patient empowerment Effective CDM = Shared care

28. Shared Care? Increasing numbers Economic drivers CDM policy Accessibility Evidence based intervention strategies to be addressed largely in Primary care Primary care need to be assured that specialist secondary care services can be accessed for their CD patients who –Fail to respond to treatment guidelines –Deteriorate despite recommended target treatment

29. CKD: A Typical GP Practice of 10000 Stage 1 Stage 5 Stage 4 Stage 3 Stage 2 460 60 6 380 90 60 15 30eGFR

30. Conclusion Series of innovations since 2001 to manage diabetic nephropathy in our region – ongoing process Enhanced the collaboration between Primary and Secondary care to manage this condition Developing approaches to promote self- management in line with CDM strategy ACR testing – likelihood of unnecessary duplication

31. Thank You